Johnson & Johnson (JNJ) Tops Q1 EPS by 7c, Revenue Slightly Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Johnson & Johnson (JNJ) Tops Q1 EPS by 7c, Revenue Slightly Misses
April 17, 2024 7:05 AM EDT
RBC Capital analyst Shagun Singh lowered the price target on Johnson & Johnson (NYSE: JNJ) to $175.00 (from $181.00) while maintaining a Outperform rating.
The analyst comments "JNJ's stock traded modestly lower post-Q1'24, where it delivered inline sales and EPS beat. JNJ tightened FY24 operational guidance... More
April 17, 2024 5:12 AM EDT
BofA Securities analyst Geoff Meacham lowered the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $180.00) while maintaining a Neutral rating.
The analyst comments "JNJ shares traded down today (-2.0%; DRG -0.3%) despite a solid 1Q and reported guidance midpoint unchanged, which we suspect was due to disappointing Carvykti sales (-1% q/q) and Vision business (-3% y/y).... More
April 16, 2024 6:45 AM EDT
Johnson & Johnson (NYSE: JNJ) reported mixed financial results for the first quarter of 2024, with adjusted earnings per share (EPS) slightly surpassing analyst expectations, while revenue fell marginally short of estimates. The healthcare giant posted an adjusted EPS of $2.71, which was $0.07 higher than the consensus estimate of $2.64. However, quarterly revenue was a hair's breadth away from consensus, coming in at $21.38 billion against... More
